Targeted Nanomedicine for Breast Cancer Therapy

1st Edition - August 6, 2022
Editors: Shivani Rai Paliwal, Rishi Paliwal
Language: English
Paperback ISBN:
9 7 8 - 0 - 1 2 - 8 2 4 4 7 6 - 0
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 8 6 0 0 4 - 8

Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strate… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Targeted Nanomedicine for Breast Cancer Therapy provides a compilation of treatment approaches for breast cancer, including conventional receptor targeting methods and novel strategies like stimuli responsive methods and tumor micro-environment responsive strategies. This book compiles the most important information on the state-of-the-art therapeutics, including breast cancer biomarkers and design principles of bio-responsive nanosystems. Presented in two parts, sections cover basic and receptor mediated targeting approaches and examine tumor microenvironment mediated approaches. This is a useful book for pharmaceutical scientists and basic and clinical scientists working in the research area of breast cancer and drug discovery both from academics and industry.

Worldwide, breast cancer is the most common cancer in women, however, breast cancer therapy is always challenging. This book aims to help researchers remain updated on the most targeted nanomedicine research available.

Cover image
Title page
Table of Contents
Copyright
List of contributors
Part A
Chapter 1. Breast cancer: introduction
Abstract
1.1 Introduction: background and epidemiology
1.2 Breast: anatomy
1.3 Breast: hormonal physiology
1.4 Breast cancer: types
1.5 Breast cancer: biomarker-based classification
1.6 Breast cancer: stages
1.7 Diagnostic measures for breast cancer
1.8 Breast cancer therapy
1.9 Barriers in tumor-directed drug delivery to breast cancer
1.10 Conclusion
References
Chapter 2. Basics of targeted nanodrug delivery of chemotherapeutics for breast cancer therapy
Abstract
2.1 Introduction
2.2 Breast cancer targeting: utilization of tumor characteristics
2.3 Microenvironment
2.4 Targeted nanodrug delivery to breast cancer
2.5 Conclusion
References
Chapter 3. Molecular targets of breast cancer for targeted nanomedicine
Abstract
3.1 Introduction
3.2 Molecular targets of breast cancer: an overview
3.3 Targeting human epidermal growth receptor
3.4 Targeting hormone receptors in breast cancer
3.5 Molecular targets for triple-negative breast cancer
3.6 Other molecular targeting strategies for breast cancer nanotherapy
3.7 Future challenges for targeted nanotherapy of breast cancer
3.8 Conclusions
References
Chapter 4. Current status of nanomedicine for breast cancer treatment
Abstract
4.1 Introduction
4.2 Marketed nanoformulations
4.3 Nanoformulations in clinical trials
4.4 Advancements in preclinical research
4.5 Conclusions and future perspectives
References
Chapter 5. Targeted nanomedicine delivery to human epidermal growth receptor
Abstract
5.1 Introduction
5.2 Pathogenesis and types of breast cancer
5.3 Human epidermal growth factor receptor (HER or EGFR) family tree
5.4 Biomarkers
5.5 Metastasis and breast cancer resistance
5.6 Nanotechnology-mediated HER-2-targeted therapeutics delivery
5.7 Future prospects
References
Chapter 6. Cell-selective breast cancer targeting through estrogen receptors
Abstract
6.1 Introduction
6.2 Estrogen receptor-mediated targeting
6.3 Estrogen-based targeting strategies
6.4 Estrogen-mediated diagnosis
6.5 Conclusion and future prospects
References
Chapter 7. Folate receptor-mediated targeted breast cancer nanomedicine
Abstract
7.1 Introduction
7.2 Folate structure and folic acid binding to folate receptor
7.3 Targeting strategies for nanoparticulate systems
7.4 Folate-targeted nanoparticles for breast cancer therapy
7.5 Conclusion
References
Chapter 8. Hyaluronic receptors for developing breast cancer nanomedicine
Abstract
8.1 Introduction
8.2 Structure and function of CD44
8.3 Classification of breast cancer
8.4 Nanocarrier-based drug CD44 targeting
8.5 Liposomes
8.6 Iron oxide NPs
8.7 PLGA NPs
8.8 Gold nanocarriers
8.9 Micelles
8.10 Conjugation
8.11 Miscellaneous
8.12 Alkaloids
8.13 Antiinflammatory agent-mediated CD44 targeting
8.14 Conclusion
Conflicts of interests
Acknowledgment
References
Chapter 9. Targeting triple-negative breast cancers using nanomedicine
Abstract
9.1 Introduction
9.2 Triple-negative breast cancer treatment availability
9.3 Constraints to triple-negative breast cancer therapy
9.4 Nanomedicines in triple-negative breast cancer: current status
9.5 Organic material-based nanomedicines
9.6 Polymer-based nanomedicines
9.7 Inorganic material-based nanomedicines
9.8 Carbon-based nanomedicines
9.9 Advanced nanotherapeutics for triple-negative breast cancer therapy
9.10 Conclusion
Abbreviations
Acknowledgment
References
Chapter 10. Tumor adhesion molecule targeting for breast cancer nanomedicine
Abstract
10.1 Introduction
10.2 Cell adhesion molecules
10.3 Cell adhesion molecules in cancer prognosis
10.4 Cell adhesion molecules in cancer diagnosis
10.5 Cell adhesion molecule targeting in cancer treatment
10.6 Nanocarrier-associated cell adhesion molecule in breast cancer treatment
10.7 Conclusion and future perspectives
References
Chapter 11. Nanomedicine for targeting breast cancer stem cells
Abstract
11.1 Introduction
11.2 Biologic characteristics of breast cancer stem cells
11.3 Signaling pathways
11.4 Challenges in the treatment of breast cancer stem cells
11.5 Nanomedicine in breast cancer stem cell therapy
11.6 Combination therapy to target breast cancer stem cells
11.7 Conclusion and future perspective
Acknowledgments
Conflict of interest
References
Part B
Chapter 12. Tumor microenvironment-mediated targeted drug delivery to breast cancer cells
Abstract
12.1 Introduction
12.2 Role of tumor microenvironment in breast cancer
12.3 Tumor microenvironment-mediated targeted drug delivery
12.4 Conclusion
References
Chapter 13. pH-responsive nanomedicine for breast cancer targeting
Abstract
13.1 Introduction
13.2 Mechanisms of destabilization of nanosystems in response to pH
13.3 pH-responsive nanosystems in breast cancer therapy
13.4 pH-sensitive micelles in breast cancer
13.5 pH-sensitive polymeric nanocarriers
13.6 pH-sensitive core–shell nanoparticles
13.7 pH-sensitive liposomes
13.8 Conclusion
Acknowledgment
References
Chapter 14. Thermosensitive liposomes for targeted breast cancer therapy
Abstract
14.1 Introduction
14.2 Hyperthermia in breast cancer therapy
14.3 Thermosensitive liposomes
14.4 Conclusions
References
Chapter 15. Hypoxia mediated targeted nanomedicine for breast cancer
Abstract
Graphical abstract
15.1 Introduction
15.2 Breast cancer
15.3 Hypoxia and cancer
15.4 Hypoxia mediated nanomedicine for breast cancer
15.5 Challenges and prospects
15.6 Conclusion
Acknowledgment
References
Chapter 16. Redox-responsive nanomedicine for breast cancer therapy
Abstract
16.1 Introduction
16.2 Mechanism
16.3 Applications of various redox-responsive nanocarriers for the treatment of breast cancer
16.4 Conclusion
References
Chapter 17. Targeted breast cancer nanotheranostics
Abstract
17.1 Introduction
17.2 Breast cancer diagnosis
17.3 Nanotheranostics for breast cancer
17.4 Ligand-based targeted nanotheranostics
17.5 Tumor microenvironment targeted nanotheranostics
17.6 Conclusion and future prospects
References
Chapter 18. Radionanotheranostics for breast cancer diagnosis and therapy: recent advances and future opportunities
Abstract
18.1 Introduction
18.2 The radioisotopes used in radionanotheranostic nanomedicine
18.3 Types of radionanotheranostics
18.4 Conclusion
18.5 Future prospective
Acknowledgment
References
Chapter 19. Cell-penetrating peptides (CPPs) and peptide-drug conjugate systems (PDCs): site-specific delivery of bioactive(s) for effective breast cancer therapy
Abstract
19.1 Introduction
19.2 Cell-penetrating peptides and different mechanisms for their internalization
19.3 Cell-targeting peptide in breast cancer therapy
19.4 Peptide–drug conjugates in breast cancer therapy
19.5 Cell-penetrating peptide-based peptide–drug conjugates in breast cancer therapy
19.6 Conclusion and future perspective
Acknowledgment
References
Further reading
Index

Purchase options

Save 50% on book bundles

Institutional subscription on ScienceDirect

Shivani Rai Paliwal

Rishi Paliwal